EcoR1 reports 5.8% stake in Alto Neuroscience
Alto Neuroscience, Inc. has a significant shareholder group led by EcoR1 Capital.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Alto Neuroscience, Inc. has a significant shareholder group led by EcoR1 Capital. EcoR1 Capital, LLC and its control person, Oleg Nodelman, each report beneficial ownership of 2,232,000 shares of Alto Neuroscience common stock, representing 5.8% of the class. EcoR1 Capital Fund Qualified, L.P. reports beneficial ownership of 2,065,935 shares, or 5.3% of the common stock. These percentages are calculated using 38,829,167 shares outstanding following the closing of an offering described in a July 14, 2026 prospectus. The reporting persons have no sole voting or dispositive power over the shares but share voting and dispositive power in the amounts reported. They state that the securities were acquired and are held without the purpose or effect of changing or influencing control of Alto Neuroscience.
Key Figures
Key Terms
beneficial owner regulatory
pecuniary interest financial
Schedule 13G regulatory
dispositive power financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Alto Neuroscience (ANRO) does EcoR1 Capital beneficially own?
Does EcoR1 Capital have control intent over Alto Neuroscience (ANRO)?
What voting power does EcoR1 Capital report for its Alto Neuroscience (ANRO) stake?
Who are the reporting persons in the Alto Neuroscience (ANRO) Schedule 13G?
AI-generated analysis. How Rhea-AI works. Not financial advice.